ImpediMed Oncology
1 FOLLOWERS
Secondary lymphedema is a leading post-treatment complication for many cancer patients, costing the U.S. healthcare system an estimated $7 billion annually.1 Of the nearly 17 million cancer survivors in the U.S., roughly one in three treated for the cancers below will develop chronic lymphedema.2,3
Lymphedema is a risk for women and men treated with surgery, radiation or Taxane-based..
ImpediMed Oncology
1M ago
ImpediMed Oncology
1y ago
ImpediMed Oncology
1y ago
ImpediMed Oncology
1y ago
ImpediMed Oncology
1y ago
ImpediMed Oncology
1y ago